Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 123

1.

Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis.

Jones AP, Trend S, Byrne SN, Fabis-Pedrini MJ, Geldenhuys S, Nolan D, Booth DR, Carroll WM, Lucas RM, Kermode AG, Hart PH.

Clin Transl Immunology. 2017 May 26;6(5):e143. doi: 10.1038/cti.2017.18. eCollection 2017 May.

2.

Evolving Identification of Blood Cells Associated with Clinically Isolated Syndrome: Importance of Time since Clinical Presentation and Diagnostic MRI.

Trend S, Jones AP, Geldenhuys S, Byrne SN, Fabis-Pedrini MJ, Nolan D, Booth DR, Carroll WM, Lucas RM, Kermode AG, Hart PH.

Int J Mol Sci. 2017 Jun 15;18(6). pii: E1277. doi: 10.3390/ijms18061277.

3.
4.

IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.

Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K, Irving WL, Dore GJ, Sheridan D, Grønbæk H, Abate ML, Hartmann R, Bugianesi E, Spengler U, Rojas A, Booth DR, Weltman M, Mollison L, Cheng W, Riordan S, Mahajan H, Fischer J, Nattermann J, Douglas MW, Liddle C, Powell E, Romero-Gomez M, George J; International Liver Disease Genetics Consortium (ILDGC).

Nat Genet. 2017 May;49(5):795-800. doi: 10.1038/ng.3836. Epub 2017 Apr 10.

PMID:
28394349
5.

Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis.

Fewings N, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR.

Data Brief. 2017 Feb 21;11:364-370. doi: 10.1016/j.dib.2017.02.040. eCollection 2017 Apr.

6.

Narrowband UVB Phototherapy for Clinically Isolated Syndrome: A Trial to Deliver the Benefits of Vitamin D and Other UVB-Induced Molecules.

Hart PH, Lucas RM, Booth DR, Carroll WM, Nolan D, Cole JM, Jones AP, Kermode AG.

Front Immunol. 2017 Jan 24;8:3. doi: 10.3389/fimmu.2017.00003. eCollection 2017.

7.

The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis.

Fewings NL, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR.

J Autoimmun. 2017 Mar;78:57-69. doi: 10.1016/j.jaut.2016.12.006. Epub 2017 Jan 4.

PMID:
28063629
8.

IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection.

O'Connor KS, Read SA, Wang M, Schibeci S, Eslam M, Ong A, Weltman MD, Douglas MW, Mazzola A, Craxì A, Petta S, Stewart GJ, Liddle C, George J, Ahlenstiel G, Booth DR.

Genes Immun. 2016 Sep;17(6):328-34. doi: 10.1038/gene.2016.27. Epub 2016 Jun 16.

9.

Cistromic and genetic evidence that the vitamin D receptor mediates susceptibility to latitude-dependent autoimmune diseases.

Booth DR, Ding N, Parnell GP, Shahijanian F, Coulter S, Schibeci SD, Atkins AR, Stewart GJ, Evans RM, Downes M, Liddle C.

Genes Immun. 2016 Jun;17(4):213-9. doi: 10.1038/gene.2016.12. Epub 2016 Mar 17.

10.

Differences in common heritable blood immune cell populations may underlie MS susceptibility and progression.

Booth DR, Fewings NL, Parnell GP, McKay FC, Stewart GJ.

Mult Scler J Exp Transl Clin. 2016 Mar 11;2:2055217316637087. doi: 10.1177/2055217316637087. eCollection 2016 Jan-Dec.

11.

Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.

Eslam M, Mangia A, Berg T, Chan HL, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA, Najim MA, Miele L, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Romero-Gomez M, Spengler U, Nattermann J, Rahme A, Sheridan D, Booth DR, McLeod D, Powell E, Liddle C, Douglas MW, van der Poorten D, George J; International Liver Disease Genetics Consortium.

Hepatology. 2016 Jul;64(1):34-46. doi: 10.1002/hep.28475. Epub 2016 Mar 30.

12.

The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.

McKay FC, Gatt PN, Fewings N, Parnell GP, Schibeci SD, Basuki MA, Powell JE, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Burke T, Vucic S, Stewart GJ, Booth DR.

Clin Immunol. 2016 Feb;163:96-107. doi: 10.1016/j.clim.2015.12.015. Epub 2016 Jan 4.

PMID:
26762769
13.

FibroGENE: A gene-based model for staging liver fibrosis.

Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A, Chan HLY, Irving WL, Sheridan D, Abate ML, Adams LA, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Nattermann J, Riordan S, Miele L, Kelaeng KS, Ampuero J, Ahlenstiel G, McLeod D, Powell E, Liddle C, Douglas MW, Booth DR, George J; International Liver Disease Genetics Consortium (ILDGC).

J Hepatol. 2016 Feb;64(2):390-398. doi: 10.1016/j.jhep.2015.11.008. Epub 2015 Dec 1.

14.

Hepatitis C Virus Driven AXL Expression Suppresses the Hepatic Type I Interferon Response.

Read SA, Tay ES, Shahidi M, O'Connor KS, Booth DR, George J, Douglas MW.

PLoS One. 2015 Aug 27;10(8):e0136227. doi: 10.1371/journal.pone.0136227. eCollection 2015.

15.

A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.

Gu BJ, Field J, Dutertre S, Ou A, Kilpatrick TJ, Lechner-Scott J, Scott R, Lea R, Taylor BV, Stankovich J, Butzkueven H, Gresle M, Laws SM, Petrou S, Hoffjan S, Akkad DA, Graham CA, Hawkins S, Glaser A, Bedri SK, Hillert J, Matute C, Antiguedad A; ANZgene Consortium, Wiley JS.

Hum Mol Genet. 2015 Oct 1;24(19):5644-54. doi: 10.1093/hmg/ddv278. Epub 2015 Jul 17.

PMID:
26188005
16.

The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function.

Field J, Shahijanian F, Schibeci S; Australia and New Zealand MS Genetics Consortium (ANZgene), Johnson L, Gresle M, Laverick L, Parnell G, Stewart G, McKay F, Kilpatrick T, Butzkueven H, Booth D.

PLoS One. 2015 Jun 11;10(6):e0127080. doi: 10.1371/journal.pone.0127080. eCollection 2015.

17.

Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.

Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Powell E, Nattermann J, Riordan S, McLeod D, Armstrong NJ, Douglas MW, Liddle C, Booth DR, George J, Ahlenstiel G; International Hepatitis C Genetics Consortium (IHCGC).

Nat Commun. 2015 Mar 5;6:6422. doi: 10.1038/ncomms7422.

18.

Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton.

Dale RC, Tantsis EM, Merheb V, Kumaran RY, Sinmaz N, Pathmanandavel K, Ramanathan S, Booth DR, Wienholt LA, Prelog K, Clark DR, Guillemin GJ, Lim CK, Mathey EK, Brilot F.

Neurol Neuroimmunol Neuroinflamm. 2014 May 22;1(1):e12. doi: 10.1212/NXI.0000000000000012. eCollection 2014 Jun.

19.

Impact of common risk factors of fibrosis progression in chronic hepatitis C.

Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, Moradpour D, Cerny A, Malinverni R, Booth DR, Suppiah V, George J, Argiro L, Halfon P, Bourlière M, Talal AH, Jacobson IM, Patin E, Nalpas B, Poynard T, Pol S, Abel L, Kutalik Z, Negro F.

Gut. 2015 Oct;64(10):1605-15. doi: 10.1136/gutjnl-2014-306997. Epub 2014 Sep 11.

PMID:
25214320
20.

Whole blood transcriptomic analysis to identify clinical biomarkers of drug response.

Parnell GP, Booth DR.

Methods Mol Biol. 2014;1175:35-43. doi: 10.1007/978-1-4939-0956-8_3.

PMID:
25150865

Supplemental Content

Loading ...
Support Center